NCT06521996: A trial that was reported late by GELLC (Grupo Español de Leucemia Linfocítica Crónica)
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT06521996 |
|---|---|
| Title | CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish CLL Group |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 26, 2024 |
| Completion date | June 30, 2028 |
| Required reporting date | June 30, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Sept. 10, 2025 |
| Days late | None |